Pricing Log in Create free account
Friday 6 November 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue
+64.0%
EPS
+525.8%
Free cash flow
+161.0%

Quarter to September 2026, against a year earlier

72.63 1.00 +1.40%
Market cap
$7.8B
P/E
47.5×
Fwd P/E
39.8×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Corcept Therapeutics Incorporated 10-Q filed Jul 29, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:09 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 30, 2026: 5 added · 3 removed · 36 modified; 3 with only figures updated

  1. Modified · Overview

    Our Hypercortisolism Products. We sell Korlym and a our authorized generic version of Korlym in the United States (our “Hypercortisolism Products”) using sales representatives to call on physicians caring for patients with hypercortisolism. We also have a field-based force of medical science liaisons. From 2017 to 2025, we used We use an exclusive specialty pharmacy vendor, Optime CareCurant Health Georgia, Inc.LLC (“OptimeCurant”) and a specialty distributor to distribute our Hypercortisolism Products and provide logistical support directly to physicianspatients and provide patients. In June 2025, we notified Optime that it would cease and physicians with logistical and pharmacy support. From 2017 to be2025, our exclusive specialty pharmacy, and in October 2025 was Optime Care, we delivered a notice of termination of our agreement with them, which became effective February 4, 2026Inc. In the fourth quarter of 2025 and in January and February 2026, we transferred all of We use a specialty distributor to distribute our specialty pharmacy services Hypercortisolism Products to Curant Health Georgia, LLC (“Curant”)hospital pharmacies and other purchasers.